The U.S. Food and Drug Administration approved aducanumab based on evidence that it reduced buildup of beta amyloid (shown in a positron emission tomography scan) in the brains of people with Alzheimer’s disease. SEVIGNY ET AL., NATURE, 537, 50 (2016) By Kelly ServickJun. 7, 2021 , 3:00 PM The antibody aducanumab today became […]